Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329628 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,541
- Enrollment target
NCT00329628 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 4,541 participants.
The verdict
NCT00329628, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,541 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
Interventions
- DRUG Enoxaparin
- DRUG Rivaroxaban (BAY59-7939)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,541 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329628
The ClinicalTrials.gov registry entry for NCT00329628 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,541 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin is the first listed.
NCT00329628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329628 about?
NCT00329628 is a clinical study titled "Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin". The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
What is the current status of trial NCT00329628?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,541 participants. The study started on 2006-02. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00329628?
The interventions under investigation include: Enoxaparin (DRUG), Rivaroxaban (BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT00329628?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.